Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Economic information and modeling report

Modeling overview

7 evidence topics · 6 sources

Summary: published economic evaluations

No cost-effectiveness analysis or budget impact model of rinzimetostat was identified. Published U.S. models address comparators and the combination partner. A partitioned survival model of lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel from a U.S. health care perspective (60-month horizon, 3% annual discount for costs, January 2025 dollars) estimated 0.86 versus 0.76 QALYs, mean total costs of $165,958 versus $129,700, and an ICER of $358,990 per QALY gained; results were most sensitive to the overall survival hazard ratio and the per-cycle costs of both treatments. Authors employed by Sanofi, the manufacturer of cabazitaxel, state that the model used the price of 177Lu-DOTATATE as a proxy for a per-cycle cost of $32,062. A U.S. payer cost model of third-line cabazitaxel versus a second androgen receptor-targeted agent over 18 months estimated $323,095 (17%) in avoided total costs, driven by the management of symptomatic skeletal events and end-of-life care; the CARD trial used cabazitaxel 25 mg/m2, while 20 mg/m2 is used in U.S. practice. A U.S. payer model of genomic test-directed olaparib after a new hormonal agent (2019 dollars) estimated an ICER of $116,903 per QALY in one scenario and cost savings in the other. For darolutamide, a U.S. payer budget impact model in nmCRPC for a 1-million-member plan over 5 years estimated a budget increase of $158,640 ($0.0132 PMPM) in year 1 and savings of $149,240 ($0.0124 PMPM) by year 5, and a U.S. hospitalization budget impact analysis of darolutamide plus docetaxel in metastatic hormone-sensitive prostate cancer reported a cumulative budget impact of -$9.71 per treated member per month over 5 years.

Lutetium Lu 177 vipivotide tetraxetan versus cabazitaxel: U.S. health care cost-effectiveness model

“In this study, we evaluated the impact of these benefits on the cost-effectiveness of 177Lu-PSMA-617 versus cabazitaxel from a U.S. health care perspective.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“A partitioned survival model was developed to estimate lifetime costs and health outcomes associated with 177Lu-PSMA-617 versus cabazitaxel over a 60-mo horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“OS and PFS associated with177Lu-PSMA-617 were derived from a retrospective cohort, and relative treatment effects (hazard ratios [HRs]) from the TheraP trial were applied to generate outcomes for patients treated with cabazitaxel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The analysis was conducted over a lifetime horizon of 60 mo with a 1-mo cycle length on the basis that over 99% of patients in our model transitioned to a terminal state within this period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“An annual discount of 3% for costs was applied in the analysis in accordance with recommendations from the Second U.S. Panel on Cost-Effectiveness in Health and Medicine (17).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“All costs were adjusted to January 2025 U.S. dollars using the medical care component of the Consumer Price Index (23).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“In the base case analysis, 177Lu-PSMA-617 was associated with an average of 0.86 QALYs, compared with 0.76 QALYs for cabazitaxel. The mean total costs were $165,958 for 177Lu-PSMA-617 and $129,700 for cabazitaxel, resulting in an incremental cost of $36,258 and an incremental QALY gain of 0.10. This corresponded to an ICER of $358,990/QALY gained, exceeding the highest U.S. WTP threshold of $200,000/QALY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Cost-effectiveness results were most sensitive to the OS HR, the per-cycle cost of 177Lu-PSMA-617, and the per-cycle cost of cabazitaxel.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“At WTP thresholds of $50,000/QALY, $100,000/QALY, and $200,000/QALY, the corresponding maximum cost per cycle that would make 177Lu-PSMA-617 cost-effective was $23,499, $24,885, and $27,656, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Probabilistic analyses found that 177Lu-PSMA-617 was cost-effective in 19.7% of iterations at a WTP threshold of $200,000/QALY, 4.7% at $100,000/QALY, and 2.2% at $50,000/QALY.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Cabazitaxel versus a second androgen receptor-targeted agent after docetaxel and an androgen receptor-targeted agent: U.S. payer cost model

Darolutamide in nonmetastatic castration-resistant prostate cancer: U.S. payer budget impact model